Bulk Pharmaceutical API Sources for enalaprilat

Bulk Pharmaceutical API Sources for enalaprilat

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-005-943-792
Amadis Chemical		A838696
AKos Consulting & Solutions		AKOS015840130
AKos Consulting & Solutions		AKOS015892570
Finetech Industry Limited		FT-0601597
Mcule		MCULE-3507396113
AvaChem Scientific		1676

Enalaprilat Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report details current and emerging bulk active pharmaceutical ingredient (API) sourcing landscapes for Enalaprilat, a critical component in the treatment of hypertension and heart failure. Analysis focuses on geographic distribution of manufacturing, key suppliers, regulatory considerations, and factors influencing supply chain stability.

What are the primary global manufacturing regions for Enalaprilat API?

Global manufacturing of Enalaprilat API is concentrated in Asia, with a significant portion originating from India and China. These regions benefit from lower manufacturing costs and established chemical synthesis infrastructure. Europe also maintains some production capacity, often focusing on higher-purity grades or specialized formulations, though at a higher cost point. The United States has limited large-scale API manufacturing for Enalaprilat, with reliance primarily on imported supplies.

Key attributes of these regions:

• India: High volume production, cost-effectiveness, large number of manufacturers. Significant player in global generics API market.
• China: Growing manufacturing capacity, competitive pricing, increasing regulatory oversight.
• Europe: Higher quality standards, often for niche markets or regulated markets requiring stringent compliance. Higher production costs.
• United States: Minimal large-scale API production, relies heavily on imports, focus on drug product manufacturing.

Who are the leading Enalaprilat API manufacturers?

The market for Enalaprilat API is characterized by a mix of established global players and emerging manufacturers. Competition is driven by price, quality, regulatory compliance, and security of supply.

Leading manufacturers include:

• Lupin Ltd. (India): A major pharmaceutical company with extensive API manufacturing capabilities. They are a significant supplier of various cardiovascular APIs, including Enalaprilat. Their production capacity is substantial, serving both domestic and international markets.
• Dr. Reddy's Laboratories (India): Another prominent Indian pharmaceutical firm known for its robust API business. Dr. Reddy's has a strong focus on R&D and manufacturing excellence, with Enalaprilat production being a part of their portfolio.
• Sun Pharmaceutical Industries Ltd. (India): India's largest pharmaceutical company, Sun Pharma has a broad API manufacturing base. They are a consistent supplier of Enalaprilat to global markets.
• Divi's Laboratories Ltd. (India): While perhaps more known for other APIs, Divi's is a substantial player in contract manufacturing and API production, with potential capacity for Enalaprilat.
• Zhejiang Huahai Pharmaceutical Co., Ltd. (China): A leading Chinese API manufacturer with a significant global presence. Huahai is known for its large-scale production and has expanded its portfolio to include ACE inhibitors.
• Jiangsu Hengrui Medicine Co., Ltd. (China): Another significant Chinese pharmaceutical company with substantial API manufacturing capabilities, potentially producing Enalaprilat.
• Teva Pharmaceutical Industries Ltd. (Israel): While Teva is primarily known as a generics drug manufacturer, they often have in-house API production or strong sourcing partnerships for key intermediates and APIs like Enalaprilat to support their global drug product supply.
• Sanofi (France): As the originator of Enalapril (and thus implicitly Enalaprilat), Sanofi may maintain some captive production for specialized needs or legacy markets, though their primary focus would be on finished dosage forms and strategic sourcing.

This list is not exhaustive, and the market dynamics, including new entrants and consolidations, can shift rapidly. Supplier due diligence is critical.

What are the critical regulatory considerations for Enalaprilat API sourcing?

Sourcing Enalaprilat API necessitates strict adherence to global regulatory standards to ensure product quality, safety, and efficacy. These requirements vary by target market but generally include stringent Good Manufacturing Practices (GMP) and pharmacopoeial compliance.

Key regulatory aspects:

• Current Good Manufacturing Practices (cGMP): Manufacturers must comply with cGMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. Audits by these agencies or third-party certifiers are common.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facility, quality control, and stability of the API. Drug product manufacturers reference these DMFs in their marketing authorization applications.
• Pharmacopoeial Standards: Enalaprilat API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These define identity, purity, assay, and impurity limits.
• Impurity Profiles: Regulatory agencies are increasingly focused on controlling impurities, particularly genotoxic impurities. Manufacturers must demonstrate robust control over their synthesis and purification processes to meet stringent impurity limits. The presence of nitrosamine impurities, for example, has become a significant regulatory concern across various APIs.
• Quality Agreements: Pharmaceutical companies establishing supply agreements with API manufacturers must have comprehensive Quality Agreements in place. These documents define the responsibilities of both parties regarding quality control, change management, batch release, and handling of deviations.
• Site Inspections and Audits: Pharmaceutical companies are responsible for ensuring their API suppliers meet quality and regulatory requirements. This involves conducting regular site inspections and audits of manufacturing facilities to verify compliance with cGMP and other relevant standards.
• Data Integrity: Robust data integrity practices are paramount. All data related to manufacturing, testing, and quality control must be accurate, complete, and attributable. Regulatory bodies scrutinize data integrity during inspections.
• Supply Chain Security and Traceability: Regulators emphasize the need for secure and traceable supply chains to prevent counterfeiting and ensure the integrity of the API from its point of manufacture to its use in finished drug products.

What factors influence Enalaprilat API supply chain stability?

The stability of the Enalaprilat API supply chain is subject to a confluence of geopolitical, economic, and operational factors. Disruptions can arise from raw material shortages, manufacturing issues, logistical challenges, and regulatory changes.

Influencing factors:

• Geopolitical Stability: Political instability in major manufacturing regions (e.g., India, China) can disrupt production and export. Trade disputes and protectionist policies can also impact cross-border API movement.
• Raw Material Availability and Pricing: The synthesis of Enalaprilat relies on specific chemical intermediates. Shortages or significant price fluctuations in these precursor materials can directly affect the cost and availability of the final API. For example, disruptions in petrochemical supply chains can have downstream effects.
• Manufacturing Capacity and Lead Times: Production capacity for Enalaprilat API can become constrained if demand surges or if a significant manufacturer experiences operational issues (e.g., equipment failure, quality investigations). Long lead times for API production and delivery require careful inventory management.
• Regulatory Compliance and Changes: Unexpected regulatory actions, such as import alerts, warning letters, or new impurity guidelines, can lead to the disqualification of a supplier or require costly process modifications, impacting supply.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing countries can lead to temporary plant shutdowns or increased operational costs for API producers, potentially affecting supply.
• Logistical Challenges: Global shipping delays, port congestion, and increased freight costs can impact the timely delivery of API. Extreme weather events or other unforeseen circumstances can also disrupt transportation networks.
• Consolidation and Supplier Dependence: Over-reliance on a limited number of suppliers, particularly if there is industry consolidation, increases vulnerability. If a key supplier faces issues, it can create significant supply gaps.
• Quality Incidents and Recalls: Any quality issues leading to batch rejections, product recalls, or voluntary withdrawals by a manufacturer can have immediate and severe consequences for supply continuity for affected customers.
• Intellectual Property Landscape: While Enalaprilat is a well-established molecule with expired patents on the active substance itself, process patents or specific polymorphic forms could still influence manufacturing routes and supplier choices in certain jurisdictions.

How does Enalaprilat API compare to other ACE inhibitors in terms of sourcing complexity?

Enalaprilat, as a parenteral ACE inhibitor, presents a somewhat different sourcing profile compared to its orally administered prodrug, Enalapril, and other common oral ACE inhibitors like Lisinopril or Ramipril. The complexity arises from its direct activity and handling requirements, rather than solely synthesis.

Feature	Enalaprilat API	Enalapril Maleate API	Lisinopril API	Ramipril API
Chemical Nature	Active diacid; water-soluble.	Prodrug ester; orally absorbed.	Active diacid; orally absorbed.	Prodrug ester; orally absorbed.
Primary Use	Parenteral administration (IV).	Oral administration (hypertension, heart failure).	Oral administration (hypertension, heart failure).	Oral administration (hypertension, heart failure).
Sourcing Complexity	Moderate. Synthesis is well-established. Focus on purity and sterile handling for IV formulations.	Moderate. Synthesis is standard for oral generics. Broader supplier base than Enalaprilat.	Moderate. Well-established synthesis routes. Large global supply.	Moderate. Standard synthesis for oral generics.
Key Sourcing Factors	API purity, pyrogenicity, endotoxin levels, sterility of manufacturing process (if applicable to API).	API purity, dissolution profile of API (influencing tablet formulation), impurity control.	API purity, impurity control.	API purity, impurity control.
Manufacturing Regions	India, China, some European capacity.	India, China, significant global generics API production.	India, China, Europe, North America.	India, China, Europe.
Regulatory Scrutiny	Similar to other APIs, with added emphasis on parenteral quality standards.	Standard API regulatory scrutiny.	Standard API regulatory scrutiny.	Standard API regulatory scrutiny.
Market Volume	Lower volume due to niche parenteral application.	High volume, widely prescribed oral medication.	High volume, widely prescribed oral medication.	High volume, widely prescribed oral medication.

Enalaprilat API sourcing is less about the sheer volume of production compared to oral ACE inhibitors. The critical differentiator is its intended use as an injectable, which can impose stricter requirements on the API, particularly concerning sterility and endotoxin limits, even at the API stage. While the chemical synthesis itself is not exceptionally complex, the quality control parameters for parenteral grade API can add a layer of complexity and cost. The global supplier base for Enalaprilat API is consequently smaller than for widely prescribed oral ACE inhibitors.

What are the typical quality specifications for Enalaprilat API?

Typical quality specifications for Enalaprilat API are defined by major pharmacopoeias and are critical for ensuring the safety and efficacy of parenteral formulations. These specifications can vary slightly between pharmacopoeias but generally address purity, identity, and the absence of harmful contaminants.

Key specifications include:

• Appearance: White to off-white crystalline powder.
• Identification: Must conform to spectroscopic (e.g., IR) and chromatographic tests for Enalaprilat.
• Assay (Potency): Typically between 98.0% and 102.0% of Enalaprilat, calculated on the dried basis. This ensures the correct amount of active drug is present.
• Related Substances/Impurities: Strict limits are placed on known and unknown impurities. This includes specific limits for key process-related impurities and degradation products. For example, limits for Enalapril (the ester prodrug) and other synthesis byproducts are critical.
• Water Content: Usually a low limit, typically not more than 1.0%, as excess moisture can affect stability.
• Residue on Ignition (Sulfated Ash): A low limit, typically not more than 0.1%, to control inorganic impurities.
• Heavy Metals: Limits for heavy metals are specified, often not more than 10 ppm or 20 ppm.
• Residual Solvents: Limits for residual solvents used in the manufacturing process must comply with ICH guidelines (e.g., Class 1, 2, and 3 solvents).
• Bacterial Endotoxins: For APIs intended for parenteral use, this is a critical specification. Limits are typically expressed in Endotoxin Units per milligram (EU/mg) and must be very low to prevent pyrogenic reactions.
• Sterility (if applicable to API grade): While often the drug product manufacturer is responsible for terminal sterilization, some API grades may be manufactured under sterile conditions to facilitate aseptic processing of the final drug product.

These specifications are confirmed through rigorous testing by both the API manufacturer and the drug product manufacturer.

Key Takeaways

The global Enalaprilat API market is predominantly supplied by manufacturers in India and China, driven by cost advantages and established chemical synthesis infrastructure. Key suppliers include Lupin, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Zhejiang Huahai Pharmaceutical, and others. Sourcing requires strict adherence to cGMP, pharmacopoeial standards, and comprehensive regulatory documentation like DMFs. Supply chain stability is influenced by geopolitical factors, raw material availability, manufacturing capacity, and evolving regulatory landscapes. Compared to oral ACE inhibitors, Enalaprilat API sourcing has a smaller market volume, with added emphasis on parenteral quality standards such as pyrogenicity and endotoxin control.

FAQs

1. How can I verify the regulatory compliance of a potential Enalaprilat API supplier? Request recent FDA or EMA inspection reports, review their Drug Master File (DMF) status, and conduct a thorough on-site audit focusing on cGMP compliance, data integrity, and quality management systems.
2. What are the primary risks associated with relying on a single supplier for Enalaprilat API? A single supplier dependency creates significant vulnerability to production disruptions, quality issues, price increases, or unexpected regulatory actions affecting that supplier, potentially leading to critical drug shortages.
3. Are there any specific challenges related to the synthesis of Enalaprilat API? While the core synthesis is established, controlling specific impurities, achieving the required enantiomeric purity, and meeting stringent parenteral quality specifications (e.g., endotoxins) are ongoing technical considerations for manufacturers.
4. What impact does the environmental regulatory environment in China and India have on Enalaprilat API supply? Stricter environmental enforcement can lead to temporary plant closures, increased operational costs for waste treatment, and potential supply interruptions if manufacturers cannot meet new compliance standards, impacting both availability and cost.
5. How does the market for Enalaprilat API differ from that of Enalapril Maleate API? Enalaprilat API is used for direct intravenous administration, necessitating specific parenteral quality controls. Enalapril Maleate API is a prodrug for oral formulations, with a much larger market volume and a broader supplier base focused on standard oral drug API specifications.

Citations

[1] United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia (USP). Retrieved from usp.org [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from edqm.eu [3] Japanese Pharmacopoeia Secretariat. (n.d.). Japanese Pharmacopoeia (JP). Retrieved from jp.pharm.or.jp [4] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from fda.gov [5] European Medicines Agency. (n.d.). Guidance Documents. Retrieved from ema.europa.eu [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ich.org